NASDAQ$AVIR
Atea Pharmaceuticals Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Atea Pharmaceuticals reported first quarter 2025 financial results with ongoing enrollment in its Phase 3 C-BEYOND trial for HCV treatment and presented positive Phase 2 results at EASL 2025.
Atea Pharmaceuticals reported a net loss of $34.272 million for Q1 2025, an improvement from a $63.169 million loss in Q1 2024. The company is making significant progress in its Phase 3 clinical trials for HCV treatment, with ongoing enrollment in C-BEYOND and expected mid-year initiation for C-FORWARD. Cash and cash equivalents stood at $425.436 million.
- Net loss improved to $34.272 million in Q1 2025 from $63.169 million in Q1 2024.
- Research and development expenses decreased significantly to $29.584 million from $57.575 million in the prior year, primarily due to the completion of the COVID-19 Phase 3 trial.
- Enrollment is ongoing for the Phase 3 C-BEYOND trial for HCV treatment, with the C-FORWARD trial expected to begin mid-year.
- The company reduced its workforce by approximately 25% in Q1 2025, expecting $15 million in cost savings through 2027.
Headline financials
Revenue & EPS history
Atea · Revenue · Quarterly
$0
Forward guidance
Atea Pharmaceuticals is focused on advancing its Phase 3 HCV program, with C-FORWARD enrollment expected to begin mid-year 2025. The company anticipates cost savings from workforce reduction and is exploring strategic alternatives to maximize shareholder value.
Tailwinds
- Enrollment for the Phase 3 C-FORWARD trial is expected to begin mid-2025.
- The company expects approximately $15 million in cost savings through 2027 from workforce reduction.
- The Board authorized a repurchase of up to $25 million of common stock, reflecting commitment to return capital to shareholders.
- The regimen of bemnifosbuvir and ruzasvir, if approved, has the potential to increase the number of treated and cured HCV patients and disrupt the global HCV market.
- The company is actively evaluating strategic alternatives to enhance shareholder value, including partnerships, acquisitions, and asset sales.
Headwinds
- The timeline for the completion of the strategic alternatives review process is unknown.
- There is no assurance that the strategic review process will result in any particular outcome.
- The company's success is dependent on the success of its most advanced product candidates, particularly the BEM/RZR combination for HCV.
- Actual results could differ materially due to uncertainties inherent in drug discovery and development, and regulatory approval processes.
- Unexpected or unfavorable safety or efficacy data during clinical trials could negatively impact outcomes.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
+0.1%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+4.2%
Avg return
30 days after
50%
12 / 24 earnings
Positive
+16.1%
Q1 2021
Best reaction
-16.2%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q4 2025 | +11.1% | +15.1% | +8.7% | |
| Q3 2025 | -12.1% | -12.9% | -10.0% | |
| Q2 2025 | -2.6% | +1.2% | -2.6% | |
| Q1 2025 | +2.2% | +4.0% | +16.4% | |
| Q4 2024 | -0.3% | +3.3% | -7.0% | |
| Q3 2024 | -2.2% | -7.0% | -17.9% | |
| Q1 2024 | -8.2% | -9.7% | -8.4% | |
| Q4 2023 | -5.5% | -11.4% | -11.4% | |
| Q3 2023 | -10.7% | -14.0% | -10.1% | |
| Q2 2023 | +4.1% | +0.3% | -3.5% | |
| Q1 2023 | -1.2% | -3.0% | +35.8% | |
| Q4 2022 | -8.7% | -0.8% | -8.1% | |
| Q3 2022 | -12.4% | -14.4% | -24.0% | |
| Q2 2022 | -3.5% | -4.3% | -11.7% | |
| Q1 2022 | +12.9% | +36.8% | +52.7% | |
| Q4 2021 | +1.4% | -9.7% | +11.1% | |
| Q3 2021 | +6.5% | +6.5% | -25.3% | |
| Q2 2021 | -16.2% | -12.9% | -13.4% | |
| Q1 2021 | +16.1% | +18.7% | +20.4% | |
| Q2 2020 | +5.3% | -1.4% | -55.0% | |
| Q4 2020 | +5.3% | -1.4% | -55.0% | |
| Q1 2020 | +7.2% | +10.6% | +73.1% | |
| Q4 2019 | +7.2% | +10.6% | +73.1% | |
| Q3 2020 | +7.2% | +10.6% | +73.1% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro